PerkinElmer logo
PerkinElmer PKI

Annual report 2025
added 02-24-2026

report update icon

PerkinElmer Financial Statements 2011-2026 | PKI

Annual Financial Statements PerkinElmer

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 14.1 B 15.4 B 14.4 B 19.2 B - 10.8 B 9.69 B 5.82 B 5.35 B - 4.95 B 4.79 B 2.71 B 8.61 B

Shares

117 M 123 M 125 M 116 M 112 M - 111 M 110 M 109 M 113 M - 113 M 112 M 113 M 331 M

Historical Prices

- 115 124 124 172 147 92 89.8 79.2 52.3 47.2 44.4 42.1 33.7 22.7

Net Income

241 M 270 M 693 M 943 M 128 M - 228 M 238 M 234 M 212 M - 158 M 167 M 7.7 M 384 M

Revenue

2.86 B 2.76 B 2.75 B 3.83 B 861 M - 2.88 B 2.78 B 2.12 B 2.1 B - 2.24 B 2.17 B 1.92 B 1.7 B

Cost of Revenue

- - - - - - - 1.44 B - - - - - - 946 M

Gross Profit

- - - - 523 M - 1.4 B 1.34 B 1.01 B 964 M - 1 B 977 M 851 M 759 M

Operating Income

357 M 347 M 301 M 1.26 B 196 M - 362 M 324 M 296 M 251 M - 165 M 228 M 103 M 158 M

Interest Expense

- - - -3.36 M -4.72 M - 63.6 M 67 M 43.9 M 38 M - 36.3 M 49.9 M 45.8 M 15.9 M

EBITDA

762 M 775 M 732 M 1.57 B 397 M - 541 M 517 M 400 M 356 M - 327 M 346 M 202 M 268 M

Operating Expenses

- - - - - - 1.07 B 1 B 714 M 713 M - 794 M 760 M 760 M 580 M

General and Administrative Expenses

992 M 994 M 1.02 B 975 M 716 M - 809 M 812 M 590 M 587 M - 659 M 586 M 627 M 474 M

All numbers in USD currency

Quarterly Income Statement PerkinElmer

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

115 M 118 M 120 M 121 M 123 M 123 M 123 M 123 M 124 M 125 M 126 M 126 M 126 M 126 M 126 M 112 M 115 M 112 M 112 M - 112 M 111 M 111 M 111 M 111 M 111 M 111 M 110 M 111 M 110 M 110 M 110 M 110 M 110 M 109 M 112 M 109 M 109 M 110 M - 113 M 113 M 113 M 112 M 113 M 113 M 113 M 113 M 112 M 112 M 113 M 115 M 114 M 114 M 113 M 116 M 113 M 112 M 114 M

Net Income

46.7 M 53.9 M 42.2 M - 94.4 M 55.4 M 26 M - 9.5 M 35.6 M 569 M - 85.3 M 179 M 177 M 380 M 128 M 246 M 379 M - 177 M 137 M 33.7 M 64.5 M 58.6 M 69.1 M 35.4 M 71.3 M 76.5 M 64.1 M 26 M -41.1 M 91.1 M 204 M 38.6 M 68.3 M 58.1 M 63.9 M 47.5 M - 54.9 M 49 M 40.3 M 30.8 M 42.3 M 50.5 M 34.2 M 66.9 M 40.2 M 27.9 M 32.2 M -15.9 M 29.6 M 33.6 M 22.6 M 293 M 36.6 M 29.8 M 24.9 M

Revenue

699 M 720 M 665 M - 684 M 692 M 650 M - 671 M 709 M 675 M - 712 M 896 M 963 M 1.35 B 861 M 1.23 B 1.31 B - 964 M 812 M 652 M 805 M 707 M 723 M 649 M 756 M 674 M 703 M 644 M 642 M 554 M 547 M 514 M 570 M 514 M 536 M 498 M - 563 M 564 M 527 M 608 M 542 M 556 M 531 M 592 M 522 M 541 M 505 M 573 M 510 M 522 M 511 M 470 M 453 M 479 M 447 M

Cost of Revenue

324 M 328 M 289 M - 299 M 306 M 295 M - 298 M 307 M 293 M - 305 M 344 M 368 M - 338 M 543 M 523 M - 437 M 364 M 344 M - 365 M 375 M 341 M - 342 M 363 M 352 M - 285 M 289 M 274 M - 266 M 283 M 263 M - 309 M 311 M 292 M - 299 M 308 M 295 M - 289 M 299 M 280 M - 279 M 283 M 279 M - 254 M 270 M 247 M

Gross Profit

- - - - - - - - - - - - - - - 827 M - - - - 527 M 447 M 308 M 398 M 342 M 348 M 308 M 376 M 332 M 340 M 292 M 307 M 269 M 258 M 240 M 268 M 249 M 254 M 235 M - 239 M 238 M 219 M 278 M 243 M 248 M 236 M 277 M 233 M 242 M 224 M 262 M 231 M 239 M 232 M 209 M 199 M 209 M 200 M

Operating Income

81.9 M 90.8 M 72.2 M - 98.2 M 85.7 M 44.1 M - 69.2 M 78.1 M 76.1 M - 111 M 232 M 262 M 510 M 196 M 332 M 468 M - 248 M 176 M 44.7 M 138 M 78.7 M 91.7 M 53.3 M 116 M 80.2 M 88.1 M 39.9 M 93.6 M 78 M 74.2 M 49.8 M 77.2 M 75.8 M 66.3 M 60.6 M - 67.4 M 59.5 M 46.8 M 30.6 M 58.8 M 69.6 M 51.8 M 92.9 M 58 M 40.2 M 36.7 M -30.8 M 43.2 M 49.8 M 36.4 M 48.8 M 36.1 M 39.4 M 41.4 M

Interest Expense

- - - - - 24.7 M 24.4 M - 25.5 M 26 M 22.7 M - 25.9 M 27.1 M 28.4 M - 43.5 M 16.8 M 14.1 M - 12.1 M 11.6 M 13.7 M - 16.1 M 17.2 M 15.8 M - 16.7 M 16.4 M 17.6 M - 11 M 10.7 M 10.9 M - 11 M 9.94 M 9.84 M - 9.87 M 9.3 M 9.39 M - 8.91 M 9.08 M 9.22 M - 11.7 M 11.9 M 11.7 M - 11.4 M 11.3 M 11.4 M - 4.45 M 4.21 M 3.92 M

EBITDA

99.9 M 108 M 170 M - 116 M 102 M 152 M - 160 M 171 M 185 M - 202 M 326 M 371 M 510 M 393 M 478 M 538 M - 431 M 296 M 105 M 138 M 236 M 196 M 104 M 116 M 214 M 176 M 84.4 M 93.6 M 154 M 124 M 74.6 M 77.2 M 150 M 117 M 86 M - 151 M 116 M 75.1 M 30.6 M 146 M 128 M 81.1 M 92.9 M 153 M 102 M 67.3 M -30.8 M 138 M 114 M 68.4 M 48.8 M 115 M 90 M 65.4 M

General and Administrative Expenses

242 M 249 M 250 M - 238 M 252 M 261 M - 250 M 267 M 249 M - 243 M 263 M 275 M - 276 M 282 M 251 M - 225 M 221 M 209 M - 204 M 202 M 199 M - 197 M 205 M 200 M - 153 M 150 M 147 M - 143 M 151 M 145 M - 148 M 147 M 146 M - 143 M 147 M 152 M - 143 M 148 M 151 M - 145 M 150 M 157 M - 133 M 138 M 133 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements PerkinElmer PKI
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting PerkinElmer plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 116.98 2.73 % $ 35.6 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 25.38 2.19 % $ 705 M usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 196.17 2.7 % $ 140 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 16.27 2.23 % $ 492 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 17.97 1.7 % $ 958 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Guardant Health Guardant Health
GH
$ 94.63 1.43 % $ 11.9 B usaUSA
DexCom DexCom
DXCM
$ 65.54 3.85 % $ 25.6 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.28 1.18 % $ 178 M chinaChina
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 5.85 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 109.05 1.76 % $ 8.99 B irlandaIrlanda
Illumina Illumina
ILMN
$ 128.09 1.3 % $ 20.4 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 174.65 2.42 % $ 30 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Lantheus Holdings Lantheus Holdings
LNTH
$ 80.09 2.57 % $ 5.41 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 176.44 4.03 % $ 8.75 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Medpace Holdings Medpace Holdings
MEDP
$ 524.94 3.23 % $ 15.1 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 318.47 3.81 % $ 27.2 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 4.84 2.0 % $ 448 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.37 3.85 % $ 1.07 B usaUSA
Biodesix Biodesix
BDSX
$ 14.52 -0.08 % $ 1.88 B usaUSA
Natera Natera
NTRA
$ 212.81 1.69 % $ 20.9 B usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.49 3.12 % $ 447 M usaUSA
Precipio Precipio
PRPO
$ 27.77 -2.56 % $ 44.6 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Personalis Personalis
PSNL
$ 6.48 5.02 % $ 384 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 274.08 1.83 % $ 22.8 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.68 -0.37 % $ 87 K usaUSA
Biomerica Biomerica
BMRA
$ 2.15 -0.46 % $ 4.94 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.18 0.85 % $ 6.43 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 2.0 0.25 % $ 8.85 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael